BIOTECHNOLOGY VALUE FUND LP 13D and 13G filings for Viracta Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:33 pm Sale | 2024-09-30 | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND LP | 0 0.000% | -3,833,785 (Position Closed) | Filing |
| 2023-02-13 5:53 pm Purchase | 2022-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND LP | 3,833,785 9.980% | 102,041 (+2.73%) | Filing |
| 2022-02-14 1:33 pm Purchase | 2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND LP | 3,731,744 9.900% | 3,731,744 (New Position) | Filing |